{"id":"janumet-lantus","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Gastrointestinal disturbance (nausea, diarrhea)"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions (Lantus)"}]},"_chembl":{"chemblId":"CHEMBL1201497","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Janumet works through dual action: sitagliptin inhibits dipeptidyl peptidase-4 to prolong GLP-1 and GIP activity, stimulating insulin secretion in response to meals, while metformin decreases hepatic glucose output and improves insulin sensitivity. Lantus (insulin glargine) is a basal insulin analog that provides continuous glucose-lowering effect over 24 hours by mimicking the body's natural background insulin secretion. Together, these agents address multiple pathways in type 2 diabetes pathophysiology.","oneSentence":"Janumet combines sitagliptin (a DPP-4 inhibitor) with metformin to lower blood glucose by increasing incretin levels and reducing hepatic glucose production, while Lantus is a long-acting basal insulin that provides steady glucose control.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:50:36.320Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus (Janumet as oral agent; Lantus as basal insulin therapy)"}]},"trialDetails":[{"nctId":"NCT02623998","phase":"PHASE3","title":"Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita)","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2016-07-09","conditions":"Type 2 Diabetes Mellitus","enrollment":102},{"nctId":"NCT02250794","phase":"PHASE4","title":"Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2014-10","conditions":"Type 2 Diabetes Mellitus","enrollment":""},{"nctId":"NCT02738879","phase":"PHASE3","title":"Randomized Sitagliptin Withdrawal Study (MK-0431-845)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-05-09","conditions":"Type 2 Diabetes Mellitus","enrollment":746},{"nctId":"NCT02036515","phase":"PHASE3","title":"Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-12","conditions":"Type 2 Diabetes Mellitus","enrollment":464},{"nctId":"NCT01845831","phase":"PHASE4","title":"Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2013-08","conditions":"Type 2 Diabetes","enrollment":292},{"nctId":"NCT01269996","phase":"PHASE4","title":"JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2011-05","conditions":"Type 2 Diabetes Mellitus","enrollment":71},{"nctId":"NCT01717911","phase":"PHASE4","title":"ß-Cell Function and Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients With Moderate Hyperglycemia","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2010-09","conditions":"Type 2 Diabetes","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Janumet, Lantus","genericName":"Janumet, Lantus","companyName":"Chinese University of Hong Kong","companyId":"chinese-university-of-hong-kong","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Janumet combines sitagliptin (a DPP-4 inhibitor) with metformin to lower blood glucose by increasing incretin levels and reducing hepatic glucose production, while Lantus is a long-acting basal insulin that provides steady glucose control. Used for Type 2 diabetes mellitus (Janumet as oral agent; Lantus as basal insulin therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}